CellPoint Diagnostics is an early stage company developing diagnostic, monitoring, and molecular analytical tools for cancer. Our novel, proprietary technology captures and analyzes circulating tumor cells ("CTCs") directly from patient blood. Scientific and clinical data have demonstrated that CTCs are derived from the primary tumor, and the assessment of the number of CTCs in the blood has been shown to accurately predict survival for cancer patients.

Our goal is to commercialize products that will provide safe, non-invasive "blood-based biopsies" which will present physicians and patients with highly accurate, real-time, individualized clinical information on disease status and treatment response. We intend to identify, diagnose and guide treatment to the specific agents of lethal metastatic cancer. This has the potential to transform cancer from a deadly disease to a chronic, managed condition and will provide a powerful tool for the development of new cancer drugs.

The company has raised over $20 million since it’s inception in 2005, and recently closed a Series A-Prime financing for over $11 million in August 2007. Major investors include Northgate Capital and Mohr Davidow Ventures. The capital is supporting operations, the advancement of the technology platform into product development, and early clinical research efforts.